Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography.

Wu HY, Zhang C, Zhao X, Qian JY, Wang QB, Ge JB.

Acta Pharmacol Sin. 2019 Sep 12. doi: 10.1038/s41401-019-0278-9. [Epub ahead of print]

PMID:
31515526
2.

Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients.

Li DD, Wang XY, Xi SZ, Liu J, Qin LA, Jing J, Yin T, Chen YD.

J Geriatr Cardiol. 2016 May;13(4):282-9. doi: 10.11909/j.issn.1671-5411.2016.04.012.

3.

Relationship between thromboelastography and long-term ischemic events as gauged by the response to clopidogrel in patients undergoing elective percutaneous coronary intervention.

Hou X, Han W, Gan Q, Liu Y, Fang W.

Biosci Trends. 2017 May 23;11(2):209-213. doi: 10.5582/bst.2016.01233. Epub 2017 Mar 19.

4.

Evaluation of the TEG platelet mapping assay in blood donors.

Bochsen L, Wiinberg B, Kjelgaard-Hansen M, Steinbr├╝chel DA, Johansson PI.

Thromb J. 2007 Feb 20;5:3.

5.

Association of thrombelastographic parameters with post-stenting ischemic events.

Wang B, Li XQ, Ma N, Mo D, Gao F, Sun X, Xu X, Liu L, Song L, Li XG, Zhao Z, Zhao X, Miao ZR.

J Neurointerv Surg. 2017 Feb;9(2):192-195. doi: 10.1136/neurintsurg-2015-011687. Epub 2015 Jun 3.

PMID:
26041100
6.

Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes.

Lu D, Owens J, Kreutz RP.

Thromb Res. 2013 Aug;132(2):e94-8. doi: 10.1016/j.thromres.2013.07.012. Epub 2013 Aug 3.

7.

Thromboelastograph with Platelet Mapping(TM) predicts postoperative chest tube drainage in patients undergoing coronary artery bypass grafting.

Chowdhury M, Shore-Lesserson L, Mais AM, Leyvi G.

J Cardiothorac Vasc Anesth. 2014 Apr;28(2):217-23. doi: 10.1053/j.jvca.2013.12.010.

PMID:
24630471
8.

Changes in platelet function with inflammation in patients undergoing vascular surgery.

Olechowski B, Khanna V, Mariathas M, Ashby A, Dalton RT, Nordon I, Englyst N, Harris S, Nicholas Z, Thayalasamy K, Mahmoudi M, Curzen N.

Platelets. 2019;30(2):190-198. doi: 10.1080/09537104.2017.1392498. Epub 2017 Dec 11.

PMID:
29227173
9.

The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.

Tang N, Yin S, Sun Z, Xu X, Qin J.

Scand J Clin Lab Invest. 2015 May;75(3):223-9. doi: 10.3109/00365513.2014.993696. Epub 2015 Jan 16.

PMID:
25594796
10.

Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events.

Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, Antonino MJ, Tantry US, Cohen E.

Am Heart J. 2010 Aug;160(2):346-54. doi: 10.1016/j.ahj.2010.05.034.

11.

Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease?

Khanna V, Mikael R, Thayalasamy K, Sambu N, Dimitrov BD, Englyst N, Calver AL, Corbett S, Gray H, Simpson IA, Wilkinson JR, Curzen N.

J Thromb Haemost. 2015 Jun;13(6):920-30. doi: 10.1111/jth.12909. Epub 2015 Apr 23.

12.

Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?

Swallow RA, Agarwala RA, Dawkins KD, Curzen NP.

Platelets. 2006 Sep;17(6):385-92.

PMID:
16973499
13.

On-Treatment Platelet Reactivity is a Predictor of Adverse Events in Peripheral Artery Disease Patients Undergoing Percutaneous Angioplasty.

Grifoni E, Gori AM, Giusti B, Valenti R, Migliorini A, Basili S, Paniccia R, Elmahdy MF, Pulli R, Pratesi C, Antoniucci D, Violi F, Marcucci R.

Eur J Vasc Endovasc Surg. 2018 Oct;56(4):545-552. doi: 10.1016/j.ejvs.2018.06.032. Epub 2018 Jul 17.

14.

Detection of individual responses to clopidogrel: Validation of a novel, rapid analysis using thrombelastography 6s.

Olechowski B, Dalton RT, Khanna V, Ashby A, Vavyla M, Mariathas M, Harris S, Nicholas Z, Mahmoudi M, Curzen N.

Cardiovasc Ther. 2018 Aug;36(4):e12433. doi: 10.1111/1755-5922.12433. Epub 2018 May 25.

PMID:
29682911
15.

Platelet function monitoring guided antiplatelet therapy in patients receiving high-risk coronary interventions.

Xu L, Wang L, Yang X, Li K, Sun H, Zhang D, Wang H, Li W, Ni Z, Xia K, Liu Y.

Chin Med J (Engl). 2014;127(19):3364-70.

PMID:
25269896
16.

Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.

Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS).

Cardiovasc Ther. 2016 Aug;34(4):209-15. doi: 10.1111/1755-5922.12188.

PMID:
27086085
17.

Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients.

Li X, Wang Z, Wang Q, Xu Q, Lv Q.

Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):84-93. doi: 10.1111/bcpt.13110. Epub 2018 Sep 5.

PMID:
30098132
18.

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA.

J Am Coll Cardiol. 2007 Feb 13;49(6):657-66. Epub 2007 Jan 26.

19.

CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.

Liu J, Nie XY, Zhang Y, Lu Y, Shi LW, Wang WM.

Chin Med J (Engl). 2015 Aug 20;128(16):2183-8. doi: 10.4103/0366-6999.162515.

20.

Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.

Nardin M, Verdoia M, Sartori C, Pergolini P, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group.

J Cardiovasc Pharmacol. 2015 Oct;66(4):364-70. doi: 10.1097/FJC.0000000000000288.

PMID:
26065844

Supplemental Content

Support Center